JP2020521767A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521767A5
JP2020521767A5 JP2019565399A JP2019565399A JP2020521767A5 JP 2020521767 A5 JP2020521767 A5 JP 2020521767A5 JP 2019565399 A JP2019565399 A JP 2019565399A JP 2019565399 A JP2019565399 A JP 2019565399A JP 2020521767 A5 JP2020521767 A5 JP 2020521767A5
Authority
JP
Japan
Prior art keywords
alkyl
solvate
pharmaceutically acceptable
hydrate
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019565399A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018217809A5 (enExample
JP2020521767A (ja
JP7162622B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033964 external-priority patent/WO2018217809A1/en
Publication of JP2020521767A publication Critical patent/JP2020521767A/ja
Publication of JP2020521767A5 publication Critical patent/JP2020521767A5/ja
Publication of JPWO2018217809A5 publication Critical patent/JPWO2018217809A5/ja
Application granted granted Critical
Publication of JP7162622B2 publication Critical patent/JP7162622B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019565399A 2017-05-23 2018-05-22 ピラゾールmagl阻害剤 Active JP7162622B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762510223P 2017-05-23 2017-05-23
US62/510,223 2017-05-23
PCT/US2018/033964 WO2018217809A1 (en) 2017-05-23 2018-05-22 Pyrazole magl inhibitors

Publications (4)

Publication Number Publication Date
JP2020521767A JP2020521767A (ja) 2020-07-27
JP2020521767A5 true JP2020521767A5 (enExample) 2021-07-26
JPWO2018217809A5 JPWO2018217809A5 (enExample) 2022-07-26
JP7162622B2 JP7162622B2 (ja) 2022-10-28

Family

ID=64397012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565399A Active JP7162622B2 (ja) 2017-05-23 2018-05-22 ピラゾールmagl阻害剤

Country Status (23)

Country Link
US (1) US11149037B2 (enExample)
EP (1) EP3634404B1 (enExample)
JP (1) JP7162622B2 (enExample)
KR (1) KR20200010366A (enExample)
CN (1) CN110678177B (enExample)
AU (1) AU2018273888A1 (enExample)
BR (1) BR112019024488A2 (enExample)
CA (1) CA3065898A1 (enExample)
CL (1) CL2019003398A1 (enExample)
CO (1) CO2019013016A2 (enExample)
CR (1) CR20190537A (enExample)
DO (1) DOP2019000295A (enExample)
EA (1) EA201992504A1 (enExample)
EC (1) ECSP19083923A (enExample)
ES (1) ES3005265T3 (enExample)
JO (1) JOP20190267A1 (enExample)
MA (1) MA50405A (enExample)
MX (1) MX2019014041A (enExample)
NI (1) NI201900120A (enExample)
PE (1) PE20200293A1 (enExample)
PH (1) PH12019502646A1 (enExample)
RU (1) RU2019137094A (enExample)
WO (1) WO2018217809A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
WO2017096315A1 (en) 2015-12-02 2017-06-08 The Scripps Research Institute TRIAZOLE DAGL(α) INHIBITORS
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
PT3630744T (pt) 2017-05-23 2023-03-14 H Lundbeck As Inibidores de pirazol magl
JP7269943B2 (ja) 2018-01-08 2023-05-09 エフ. ホフマン-ラ ロシュ アーゲー Magl阻害剤としてのオクタヒドロピリド[1,2-アルファ]ピラジン
KR20220034104A (ko) * 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
CN114195780A (zh) * 2020-09-18 2022-03-18 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
WO2022165513A1 (en) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CN117561058A (zh) 2021-06-26 2024-02-13 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
JP7777891B2 (ja) 2021-12-29 2025-12-01 サイ セラピューティクス インコーポレイテッド モノアシルグリセロールリパーゼ(magl)の阻害
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof
WO2025221154A1 (en) 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308130A (en) 1962-04-26 1967-03-07 Du Pont N-disubstituted carbamyl pyrazoles
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
EP1465901A4 (en) * 2002-02-19 2006-02-01 Teva Pharma PROCESS FOR THE DESOLVATION OF ATORVASTATIN HEMI-CALCIUM SOLVATES AND OF ESSENTIALLY SOLVENT-FREE ATORVASTATIN HEMI-CALCIUM
SE0300705D0 (sv) 2003-03-14 2003-03-14 Biolipox Ab New compounds
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
BRPI0923819B1 (pt) 2008-12-24 2021-11-09 Bial-Portela & Ca, S.A. Compostos inibidores de hidrolase amida de ácidos graxos, composições e usos dos mesmos
WO2012138877A1 (en) 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP3087067B1 (en) 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10323513B2 (en) * 2014-07-23 2019-06-18 Baker Hughes, A Ge Company, Llc System and method for downhole organic scale monitoring and intervention in a production well
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
EA035823B1 (ru) 2015-07-31 2020-08-17 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10519134B2 (en) 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017096315A1 (en) 2015-12-02 2017-06-08 The Scripps Research Institute TRIAZOLE DAGL(α) INHIBITORS
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
PT3630744T (pt) 2017-05-23 2023-03-14 H Lundbeck As Inibidores de pirazol magl
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Similar Documents

Publication Publication Date Title
JP2020521767A5 (enExample)
JP2020521766A5 (enExample)
RU2019137094A (ru) Ингибиторы magl на основе пиразола
JP2018526399A5 (enExample)
CN113614080A (zh) Kras g12c抑制剂化合物及其用途
JP2020507582A5 (enExample)
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
JP2019034943A5 (enExample)
JP2020521740A5 (enExample)
JP2010524899A5 (enExample)
JPWO2019013311A5 (enExample)
JP2010509284A5 (enExample)
JP2007524696A5 (enExample)
JP2016534148A5 (enExample)
JP2014506599A5 (enExample)
JP2016504378A5 (enExample)
JP2013509431A5 (enExample)
JP2016525136A5 (enExample)
JP2006507355A5 (enExample)
JP2017518959A5 (enExample)
JP2020502047A5 (enExample)
JP2019531279A5 (enExample)
JP2019537603A5 (enExample)
JP2010509285A5 (enExample)
JP2010524898A5 (enExample)